GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Researchers Validate Deep Bio's AI Model for Prostate Cancer Assessment

NextEdge Admin

07 Aug 2024

2 min 36 sec

Deep Bio Inc., a leader in AI-driven digital pathology, announced the publication of an external validation study for its DeepDx Prostate AI algorithm, conducted by Stanford Medicine. Published in the British Journal of Urology International, the study titled “External Validation of an Artificial Intelligence Model for Gleason Grading of Prostate Cancer on Prostatectomy Specimens” evaluated the algorithm's performance on whole-mount radical prostatectomy (RP) specimens.

The DeepDx Prostate algorithm, originally trained on prostate core needle biopsy (CNB) images from South Korean hospitals, was tested on RP specimens from a different institution without any fine-tuning. Key findings include:

1. High Accuracy: The algorithm achieved a sensitivity of 0.997 and specificity of 0.88 in detecting cancer in RP specimens.
2. Agreement with Pathologists: It showed strong agreement with expert uropathologists, with Cohen’s Kappa values of 0.91 for cancer presence, 0.89 for Gleason grade classification, and 0.89 for risk group identification.
3. Generalizability: The algorithm demonstrated robust performance across different datasets and tissue types, suggesting its potential for widespread implementation.

Sun Woo Kim, CEO of Deep Bio, emphasized the importance of accurate Gleason grading for optimizing treatment plans. Bogdana Schmidt MD, MPH, the lead author and assistant professor at the University of Utah, highlighted the algorithm's generalizability and potential for clinical use, noting its value in timely and accurate grading of prostate cancer.

The study concludes that DeepDx Prostate is a highly accurate tool for identifying and grading prostate cancer on digital histopathology images, showing almost perfect concordance with expert pathologists. DeepDx Prostate also demonstrates 99% sensitivity and 97% specificity when used on CNB samples.